Breaking News Instant updates and real-time market news.

APP

AppLovin

/

+

10:51
04/15/21
04/15
10:51
04/15/21
10:51

AppLovin indicated to open at $77, IPO priced at $80

AppLovin (APP) priced 25M shares at $80.00. The deal priced at midpoint of $75.00-$85.00 target range. Morgan Stanley, JPMorgan, KKR, BofA and Citi are acting as joint book running managers for the offering. AppLovin's technology platform provides developers a set of solutions to market, monetize, analyze and publish their apps.

  • 15

    Apr

TODAY'S FREE FLY STORIES

Upgrade
Credit Suisse upgraded to Buy from Hold at Berenberg » 04:48
06/24/21
06/24
04:48
06/24/21
04:48
CS

Credit Suisse

$10.20 /

+0.025 (+0.25%)

Berenberg analyst Eoin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

06/22/21 Kepler Cheuvreux
Kepler Cheuvreux downgrades European banks to Neutral from Overweight
06/16/21 JPMorgan
Credit Suisse price target raised to CHF 11.70 from CHF 11 at JPMorgan
05/27/21 Barclays
Credit Suisse price target raised to CHF 12.50 from CHF 12 at Barclays
04/28/21 UBS
Credit Suisse upgraded to Buy from Neutral at UBS
CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

CS Credit Suisse
$10.20 /

+0.025 (+0.25%)

Initiation
Beazley initiated with a Hold at Berenberg » 04:46
06/24/21
06/24
04:46
06/24/21
04:46
BZLYF

Beazley

$4.70 /

+ (+0.00%)

Berenberg analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BZLYF Beazley
$4.70 /

+ (+0.00%)

BZLYF Beazley
$4.70 /

+ (+0.00%)

06/10/21 Keefe Bruyette
Beazley upgraded to Outperform from Market Perform at Keefe Bruyette
05/14/21 Credit Suisse
Beazley price target lowered to 350 GBp from 365 GBp at Credit Suisse
04/26/21 BofA
Beazley initiated with a Buy at BofA
03/22/21 Investec
Beazley upgraded to Buy from Hold at Investec
Initiation
Phoenix Group initiated with a Hold at Berenberg » 04:45
06/24/21
06/24
04:45
06/24/21
04:45
PNXGF

Phoenix Group

$10.24 /

+ (+0.00%)

Berenberg analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PNXGF Phoenix Group
$10.24 /

+ (+0.00%)

06/09/21 Investec
Phoenix Group downgraded to Add from Buy at Investec
03/30/21 Barclays
Phoenix Group price target raised to 819 GBp from 804 GBp at Barclays
03/30/21 Morgan Stanley
Phoenix Group price target lowered to 850 GBp from 878 GBp at Morgan Stanley
02/25/21 Morgan Stanley
Phoenix Group price target lowered to 878 GBp from 888 GBp at Morgan Stanley
Initiation
Linea Directa initiated with a Buy at Berenberg » 04:43
06/24/21
06/24
04:43
06/24/21
04:43
LNDAF

Linea Directa

$2.14 /

+ (+0.00%)

Berenberg analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LNDAF Linea Directa
$2.14 /

+ (+0.00%)

06/07/21 JPMorgan
Linea Directa initiated with an Overweight at JPMorgan
General news
FX Action: USD-CAD found a footing » 04:40
06/24/21
06/24
04:40
06/24/21
04:40
$ECON

Economic Data

/

+

FX Action: USD-CAD found…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
FX Update: The dollar majors have been seeing narrow ranges » 03:55
06/24/21
06/24
03:55
06/24/21
03:55
$ECON

Economic Data

/

+

FX Update: The dollar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
European stock markets are moving higher in early trade, » 03:30
06/24/21
06/24
03:30
06/24/21
03:30
$ECON

Economic Data

/

+

European stock markets…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
Asian Market Update: » 02:05
06/24/21
06/24
02:05
06/24/21
02:05
$ECON

Economic Data

/

+

Asian Market Update: The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
U. » 02:05
06/24/21
06/24
02:05
06/24/21
02:05
$ECON

Economic Data

/

+

U.S. GDP preview:…

U.S. GDP preview: analysts expect a slight upward revision to Q1 GDP growth to 6.5% from 6.4% in the initial and second prints. This would include bump ups to consumption, retail inventories and construction, but downward knocks to net exports and wholesale inventories. The firm Q1 GDP gain documents the updraft from vaccine distributions and two rounds of fiscal stimulus over the period, alongside a seasonal Q1 pull after the Q4 downdraft attributable to the mismatch of seasonal factors with this year's disrupted holiday activities. Much of the gyration was in consumption, which stalled in Q4 but surged in Q1, alongside moderating growth in residential and nonresidential fixed investment. Inventories subtracted sharply from GDP in Q1, -2.78%, as businesses were unable to keep up with demand. Imports were robust, though gains were restrained by port backlogs, while exports have been restrained by weak growth abroad. The price index should hold at the 4.3% rate, with the core at 2.5% in the prior report (and 4.1% and 2.3% in the Advance report) compared to respective rates of 2.0% and 1.3% in Q4.

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
U. » 02:05
06/24/21
06/24
02:05
06/24/21
02:05
$ECON

Economic Data

/

+

U.S. durable goods…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
U.S. jobless claims preview: » 02:05
06/24/21
06/24
02:05
06/24/21
02:05
$ECON

Economic Data

/

+

U.S. jobless claims…

U.S. jobless claims preview: initial claims are expected to drop -22k to 390k in the week ended June 19 after the larger than expected 37k jump to 412k. The bounce capped a 6-week string of new cycle-lows, culminating with a -13k drop at the start of June to 375k. Continuing claims are seen sliding -48k to 3,470k for the June 12 week following the prior 1k uptick to 3,518k in the June 5 week. Our June nonfarm payroll estimate sits at 550k.

ShowHide Related Items >><<
$ECON Economic Data
/

+

Initiation
Beauty Health initiated with an Overweight at Piper Sandler » 21:34
06/23/21
06/23
21:34
06/23/21
21:34
SKIN

Beauty Health

$17.60 /

+0.21 (+1.21%)

Piper Sandler analyst…

Piper Sandler analyst Erinn Murphy initiated coverage of Beauty Health with an Overweight rating and $24 price target. The company plays well into the secular growth trends of accelerating interest in skincare and from medical technology device perspective, it caters to the secular shift from more invasive/intense aesthetic procedures to cost-effective and non-invasive treatment, Murphy tells investors in a research note.

ShowHide Related Items >><<
SKIN Beauty Health
$17.60 /

+0.21 (+1.21%)

SKIN Beauty Health
$17.60 /

+0.21 (+1.21%)

06/15/21 Canaccord
Canaccord starts 'category creator' Beauty Health with Buy, $21 target
06/15/21 Canaccord
Beauty Health initiated with a Buy at Canaccord
SKIN Beauty Health
$17.60 /

+0.21 (+1.21%)

SKIN Beauty Health
$17.60 /

+0.21 (+1.21%)

Syndicate
OneSpaWorld 8.42M share Spot Secondary priced at $9.50 » 20:49
06/23/21
06/23
20:49
06/23/21
20:49
OSW

OneSpaWorld

$10.20 /

-1 (-8.93%)

The deal was priced below…

The deal was priced below last closing price of $10.20. Stifel and William Blair are acting as joint book running managers for the offering.

ShowHide Related Items >><<
OSW OneSpaWorld
$10.20 /

-1 (-8.93%)

OSW OneSpaWorld
$10.20 /

-1 (-8.93%)

03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
01/13/21 Jefferies
OneSpaWorld downgraded to Hold at Jefferies following over 50% rally
01/13/21 Jefferies
OneSpaWorld downgraded to Hold from Buy at Jefferies
10/30/20 Stifel
CDC lifting 'no sail order' a 'clear positive' for cruise liners, says Stifel
OSW OneSpaWorld
$10.20 /

-1 (-8.93%)

  • 24
    Jun
OSW OneSpaWorld
$10.20 /

-1 (-8.93%)

OSW OneSpaWorld
$10.20 /

-1 (-8.93%)

Initiation
Okta initiated with a Buy at Daiwa » 20:46
06/23/21
06/23
20:46
06/23/21
20:46
OKTA

Okta

$242.62 /

+1.34 (+0.56%)

Daiwa analyst Stephen…

Daiwa analyst Stephen Bersey initiated coverage of Okta with a Buy rating and $282 price target.

ShowHide Related Items >><<
OKTA Okta
$242.62 /

+1.34 (+0.56%)

OKTA Okta
$242.62 /

+1.34 (+0.56%)

05/27/21 Canaccord
Okta becoming the standard for digital identity, says Canaccord
05/27/21 JPMorgan
Okta price target raised to $245 from $235 at JPMorgan
05/27/21 Mizuho
Okta 'nicely exceeded' billings growth forecast, says Mizuho
05/27/21 Piper Sandler
Piper Sandler sees a 'little uncertainty' following Q1 beat by Okta
OKTA Okta
$242.62 /

+1.34 (+0.56%)

OKTA Okta
$242.62 /

+1.34 (+0.56%)

OKTA Okta
$242.62 /

+1.34 (+0.56%)

OKTA Okta
$242.62 /

+1.34 (+0.56%)

Initiation
Skillsoft initiated with a Buy at B. Riley » 20:46
06/23/21
06/23
20:46
06/23/21
20:46
SKIL

Skillsoft

$9.73 /

-0.275 (-2.75%)

B. Riley initiated…

B. Riley initiated coverage of Skillsoft with a Buy rating and $14 price target.

ShowHide Related Items >><<
SKIL Skillsoft
$9.73 /

-0.275 (-2.75%)

SKIL Skillsoft
$9.73 /

-0.275 (-2.75%)

06/22/21 Citi
Skillsoft initiated with a Buy at Citi
SKIL Skillsoft
$9.73 /

-0.275 (-2.75%)

Hot Stocks
Myan wins summary judgment ruling in Kansas EpiPen class action » 20:25
06/23/21
06/23
20:25
06/23/21
20:25
MYL

Symbol now VTRS

$15.86 /

+ (+0.00%)

, VTRS

Viatris

$14.18 /

-0.04 (-0.28%)

Viatris (VTRS) announced…

Viatris (VTRS) announced that the "U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's (MYL) favor on the company's summary judgment motion in the class action related to EpiPen(R) Auto-Injector. The company is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch. The court also dismissed claims alleging that Mylan foreclosed branded competition through rebate arrangements with pharmacy benefit managers."

ShowHide Related Items >><<
VTRS Viatris
$14.18 /

-0.04 (-0.28%)

MYL Symbol now VTRS
$15.86 /

+ (+0.00%)

11/06/20 Cowen
Mylan merger with Upjohn 'will likely solve nothing,' says Cowen
09/17/20 Morgan Stanley
Court ruling eliminates hurdle for Tecfidera generics, says Morgan Stanley
09/16/20 Raymond James
Mylan exclusivity on Tecfidera generic abruptly ending, says Raymond James
08/19/20 Piper Sandler
Mylan launch puts 30% of Biogen revenue base at risk, says Piper Sandler
VTRS Viatris
$14.18 /

-0.04 (-0.28%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
VTRS Viatris
$14.18 /

-0.04 (-0.28%)

VTRS Viatris
$14.18 /

-0.04 (-0.28%)

Syndicate
Monte Rosa Therapeutics 11.7M share IPO priced at $19.00 » 20:24
06/23/21
06/23
20:24
06/23/21
20:24
GLUE

Monte Rosa Therapeutics

/

+

The deal size was…

The deal size was increased to 11.7M shares from 9.75M and priced at high end of $17.00-$19.00 range. JPMorgan, Cowen, Piper Sandler and Guggenheim are acting as joint book running managers for the offering.

ShowHide Related Items >><<
  • 24
    Jun
Syndicate
Bon Natural Life prices 2.2M share IPO at $5.00 » 20:02
06/23/21
06/23
20:02
06/23/21
20:02
BON

Bon Natural Life

$20.58 /

+ (+0.00%)

U.S. Tiger Securities,…

U.S. Tiger Securities, Inc. and Newbridge Securities Corporation are acting as co-lead book running managers, and R.F. Lafferty & Co. Inc. is acting as the joint lead book running manager.

Syndicate
Grove prices 2.2M share IPO at $5.00 per share » 19:48
06/23/21
06/23
19:48
06/23/21
19:48
GRVI

Grove

/

+

The company has received…

The company has received approval to list its common stock on the Nasdaq Capital Market under the symbol "GRVI", with trading expected to begin on June 24, 2021. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
    Periodicals
    JPMorgan tells staff they may be required to get vaccinated, Bloomberg says  19:22
    06/23/21
    06/23
    19:22
    06/23/21
    19:22
    JPM

    JPMorgan

    $151.12 /

    +0.91 (+0.61%)

     
    ShowHide Related Items >><<
    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    06/15/21 BMO Capital
    JPMorgan price target trimmed to $139 at BMO Capital on reduced NII view
    06/14/21 Evercore ISI
    Synchrony price target raised to $56 from $49 at Evercore ISI
    06/08/21 Wells Fargo
    JPMorgan price target raised to $200 from $195 at Wells Fargo
    05/06/21 JMP Securities
    Walker & Dunlop price target raised to $130 from $70 at JMP Securities
    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    JPM JPMorgan
    $151.12 /

    +0.91 (+0.61%)

    Upgrade
    GlaxoSmithKline upgraded to Hold from Sell at Deutsche Bank » 19:21
    06/23/21
    06/23
    19:21
    06/23/21
    19:21
    GSK

    GlaxoSmithKline

    $39.86 /

    +0.78 (+2.00%)

    Deutsche Bank analyst…

    Deutsche Bank analyst Emmanuel Papadakis upgraded GlaxoSmithKline to Hold from Sell with a 1,350 GBp price target.

    ShowHide Related Items >><<
    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    06/14/21 Piper Sandler
    iTeos deal 'addresses a number of needs all at once, says Piper Sandler
    06/11/21 Deutsche Bank
    GlaxoSmithKline price target raised to 1,300 GBp at Deutsche Bank
    05/27/21 Piper Sandler
    Xencorc royalty revenue streams growing, says Piper Sandler
    05/11/21 UBS
    GlaxoSmithKline price target raised to 1,370 GBp from 1,360 GBp at UBS
    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    GSK GlaxoSmithKline
    $39.86 /

    +0.78 (+2.00%)

    Hot Stocks
    Japan's PMDA renews Certara's biosimulation software license » 19:03
    06/23/21
    06/23
    19:03
    06/23/21
    19:03
    CERT

    Certara

    $26.38 /

    -0.81 (-2.98%)

    Certara announced that…

    Certara announced that the Japanese Pharmaceuticals and Medical Devices Agency, or PMDA, has renewed its licenses of Certara's Simcyp and Phoenix(TM) biosimulation software. The PMDA has been using Certara's biosimulation software since 2014.

    ShowHide Related Items >><<
    CERT Certara
    $26.38 /

    -0.81 (-2.98%)

    CERT Certara
    $26.38 /

    -0.81 (-2.98%)

    05/07/21 Barclays
    Certara price target lowered to $35 from $40 at Barclays
    03/02/21 Barclays
    Certara initiated with an Overweight at Barclays
    03/02/21 Barclays
    Certara initiated with an Overweight at Barclays
    01/05/21 Morgan Stanley
    Morgan Stanley starts Certara at Equal Weight, says fully valued
    CERT Certara
    $26.38 /

    -0.81 (-2.98%)

    • 25
      Mar
    • 11
      Dec
    CERT Certara
    $26.38 /

    -0.81 (-2.98%)

    CERT Certara
    $26.38 /

    -0.81 (-2.98%)

    On The Fly
    Fly Intel: After-Hours Movers » 18:58
    06/23/21
    06/23
    18:58
    06/23/21
    18:58
    SCS

    Steelcase

    $14.49 /

    +0.04 (+0.28%)

    , RCUS

    Arcus Biosciences

    $23.40 /

    +0.67 (+2.95%)

    , FSP

    Franklin Street

    $5.27 /

    -0.13 (-2.41%)

    , KBH

    KB Home

    $43.35 /

    +0.1 (+0.23%)

    , CNXC

    Concentrix

    $157.11 /

    +2.23 (+1.44%)

    , FUL

    H.B. Fuller

    $65.62 /

    -0.885 (-1.33%)

    , PRTG

    Portage Biotech

    $35.28 /

    +2.38 (+7.23%)

    , BNL

    Broadstone Net Lease

    $24.08 /

    +0.37 (+1.56%)

    , TALO

    Talos Energy

    $18.60 /

    +0.47 (+2.59%)

    , BYND

    Beyond Meat

    $147.37 /

    -0.47 (-0.32%)

    Check out this evening's…

    ShowHide Related Items >><<
    TALO Talos Energy
    $18.60 /

    +0.47 (+2.59%)

    SCS Steelcase
    $14.49 /

    +0.04 (+0.28%)

    RCUS Arcus Biosciences
    $23.40 /

    +0.67 (+2.95%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    FUL H.B. Fuller
    $65.62 /

    -0.885 (-1.33%)

    FSP Franklin Street
    $5.27 /

    -0.13 (-2.41%)

    CNXC Concentrix
    $157.11 /

    +2.23 (+1.44%)

    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    BNL Broadstone Net Lease
    $24.08 /

    +0.37 (+1.56%)

    SCS Steelcase
    $14.49 /

    +0.04 (+0.28%)

    05/11/21 Berenberg
    Berenberg starts 'market leader' Steelcase at Buy
    05/11/21 Berenberg
    Steelcase initiated with a Buy at Berenberg
    05/07/21 Benchmark
    Benchmark upgrades Steelcase to Buy on signs of recovery in commercial furniture
    05/07/21 Benchmark
    Steelcase upgraded to Buy from Hold at Benchmark
    RCUS Arcus Biosciences
    $23.40 /

    +0.67 (+2.95%)

    02/25/21 Barclays
    Arcus Biosciences price target raised to $45 from $40 at Barclays
    02/25/21 Mizuho
    Arcus Biosciences price target raised to $43 from $40 at Mizuho
    01/20/21 Citi
    Arcus Biosciences price target raised to $51 from $32 at Citi
    01/19/21 Wedbush
    Arcus Biosciences price target raised to $55 from $48 at Wedbush
    FSP Franklin Street
    $5.27 /

    -0.13 (-2.41%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    06/15/21 Wedbush
    Wedbush sees pullback in KB Home shares as buying opportunity
    04/15/21 Wells Fargo
    KB Home initiated with an Overweight at Wells Fargo
    03/29/21 Argus
    KB Home's new orders were 'stellar', says Argus
    03/25/21 Keefe Bruyette
    KB Home price target raised to $48 from $44 at Keefe Bruyette
    CNXC Concentrix
    $157.11 /

    +2.23 (+1.44%)

    06/15/21 Barrington
    Concentrix initiated with an Outperform at Barrington
    01/07/21 Cross Research
    Concentrix initiated with a Buy at Cross Research
    12/08/20 Stifel
    Synnex downgraded to Hold from Buy at Stifel
    12/07/20 BofA
    Concentrix initiated with a Buy at BofA
    FUL H.B. Fuller
    $65.62 /

    -0.885 (-1.33%)

    03/29/21 Deutsche Bank
    H.B. Fuller price target raised to $65 from $56 at Deutsche Bank
    03/26/21 Baird
    H.B. Fuller price target raised to $72 from $65 at Baird
    01/27/21 Deutsche Bank
    H.B. Fuller price target raised to $56 from $48 at Deutsche Bank
    01/04/21 Baird
    H.B. Fuller upgraded to Outperform, added to 2021 top picks at Baird
    PRTG Portage Biotech
    $35.28 /

    +2.38 (+7.23%)

    BNL Broadstone Net Lease
    $24.08 /

    +0.37 (+1.56%)

    06/22/21 BTIG
    Broadstone Net Lease price target raised to $27 from $21 at BTIG
    06/17/21 Goldman Sachs
    Broadstone Net Lease downgraded to Neutral from Buy at Goldman Sachs
    06/15/21
    Fly Intel: Top five analyst downgrades
    06/15/21 JPMorgan
    JPMorgan upgrades W.P. Carey on swap out of Broadstone
    TALO Talos Energy
    $18.60 /

    +0.47 (+2.59%)

    06/08/21
    Fly Intel: Top five analyst initiations
    06/08/21 Citi
    Talos Energy initiated with a Buy at Citi
    05/03/21 Roth Capital
    Talos Energy price target raised to $18 from $13 at Roth Capital
    04/13/21 Stifel
    BP discovery holds over 100MMboe of potential net to Talos interest, says Stifel
    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    06/23/21 JPMorgan
    Beyond Meat breakfast sandwich discontinued at Dunkin', says JPMorgan
    05/24/21
    Fly Intel: Top five analyst upgrades
    05/24/21 Bernstein
    Beyond Meat upgraded to Outperform from Underperform at Bernstein
    05/11/21 Barclays
    Beyond Meat price target lowered to $90 from $100 at Barclays
    TALO Talos Energy
    $18.60 /

    +0.47 (+2.59%)

    SCS Steelcase
    $14.49 /

    +0.04 (+0.28%)

    RCUS Arcus Biosciences
    $23.40 /

    +0.67 (+2.95%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    FUL H.B. Fuller
    $65.62 /

    -0.885 (-1.33%)

    CNXC Concentrix
    $157.11 /

    +2.23 (+1.44%)

    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    BNL Broadstone Net Lease
    $24.08 /

    +0.37 (+1.56%)

    • 24
      Jun
    • 24
      Jun
    • 24
      Jun
    • 09
      Dec
    • 17
      Sep
    TALO Talos Energy
    $18.60 /

    +0.47 (+2.59%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    TALO Talos Energy
    $18.60 /

    +0.47 (+2.59%)

    SCS Steelcase
    $14.49 /

    +0.04 (+0.28%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    FUL H.B. Fuller
    $65.62 /

    -0.885 (-1.33%)

    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    SCS Steelcase
    $14.49 /

    +0.04 (+0.28%)

    KBH KB Home
    $43.35 /

    +0.1 (+0.23%)

    FUL H.B. Fuller
    $65.62 /

    -0.885 (-1.33%)

    CNXC Concentrix
    $157.11 /

    +2.23 (+1.44%)

    BYND Beyond Meat
    $147.37 /

    -0.47 (-0.32%)

    Hot Stocks
    IGC completes final cohort of Phase 1 trial on Alzheimer's patients » 18:54
    06/23/21
    06/23
    18:54
    06/23/21
    18:54
    IGC

    India Globalization Capital

    $1.46 /

    -0.01 (-0.68%)

    India Globalization…

    India Globalization Capital, Inc. announced it has completed Cohort 3 of its Phase 1 clinical trial on IGC's tetrahydrocannabinol-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer's disease. As previously disclosed, IGC submitted IGC-AD1, its investigational drug candidate for Alzheimer's, to the U.S. Food and Drug Administration under Section 505(i) of the Federal Food, Drug, and Cosmetic Act. IGC received approval to proceed with the Phase 1 trial, on Alzheimer's patients, from the FDA on July 30, 2020. Cohort 3 is the final cohort in IGC's Alzheimer's Phase 1 trial. The Data and Safety Monitoring Committee for IGC's clinical trial will review the data from Cohort 3, and IGC will report its findings from all three Cohorts to the FDA.

    ShowHide Related Items >><<
    IGC India Globalization Capital
    $1.46 /

    -0.01 (-0.68%)

    IGC India Globalization Capital
    $1.46 /

    -0.01 (-0.68%)

    03/29/21 Stifel
    Stifel says New York adult use cannabis market represents $5B opportunity
    02/02/21 Craig-Hallum
    Legalization could drive '3x upside' for U.S. cannabis stocks, says Craig-Hallum
    01/29/21 Stifel
    'Goldilocks' scenario for U.S. cannabis industry in play, says Stifel
    12/04/20 Alliance Global Partners
    Alliance Global sees low odds of MORE Act passing this congressional session
    IGC India Globalization Capital
    $1.46 /

    -0.01 (-0.68%)

    IGC India Globalization Capital
    $1.46 /

    -0.01 (-0.68%)

    IGC India Globalization Capital
    $1.46 /

    -0.01 (-0.68%)

    Hot Stocks
    Box CEO: We're executing a very effective strategy » 18:48
    06/23/21
    06/23
    18:48
    06/23/21
    18:48
    BOX

    Box

    $25.22 /

    +0.02 (+0.08%)

    In an interview on…

    In an interview on CNBC's Mad Money, Aaron Levie said Box has been executing its plan to drive higher operating margins and growth rates. "We fundamentally believe there is significant upside to our stock," he added. The company did a full strategic review recently to identify what could be done to drive shareholder value, Levie noted. Box has spent a tremendous amount of time with Starboard and has listened to their ideas, he added. "We fundamentally believe as a board we have the right path forward. We don't believe board changes are warranted," Levie said.

    ShowHide Related Items >><<
    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    04/09/21 DA Davidson
    Box price target lowered to $22 from $25 at DA Davidson
    04/09/21 William Blair
    KKR investment 'strong vote of confidence' in Box, says William Blair
    04/09/21 William Blair
    KKR investment 'strong vote of confidence' in Box, says William Blair
    03/23/21 KeyBanc
    Box price target raised to $27 from $22 at KeyBanc
    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    BOX Box
    $25.22 /

    +0.02 (+0.08%)

    Get Full Fly Access

    Breaking market intelligence sent straight to you
    Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
    Up-to-date information on important industry events
    Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
    News focused on the companies in your portfolio
    Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.